EUVIMEDEUVIMED entdecken
Crossref

Timing, indications and transition patterns associated with cangrelor use in patients undergoing PCI

Angelo Oliva, Davide Cao, Mark Shneyderman, Gregory Serrao, Mauro Gitto, Francesca Maria Di Muro, Samantha Sartori, Yihan Feng, Birgit Vogel, Johny Nicolas, Joseph Sweeny, Prakash Krishnan und 9 weitere

Journal of Thrombosis and Thrombolysis · 2025

DOI: 10.1007/s11239-025-03136-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2025. Verfasst von Angelo Oliva und 20 weiteren Autor:innen. Beteiligte Einrichtung: The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, One Gustave L. L…. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Purinergic P2Y Receptor Antagonists, Platelet Aggregation Inhibitors, Adenosine Monophosphate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Deutsche Herzstiftung, Chiesi USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Optimal antiplatelet therapy is crucial in percutaneous coronary intervention (PCI) to balance thrombotic and bleeding risk. Cangrelor, a rapid-acting intravenous P2Y12 inhibitor, is particularly effective in high-risk PCI scenarios, including acute coronary syndrome (ACS) or patients unable to take oral medications. The SMILE study evaluated real-world timing, indications, and outcomes of cangrelor use, along with transition to oral P2Y12 inhibitors, in high-risk patients undergoing PCI. A retrospective analysis of Mount Sinai PCI registry was conducted, examining consecutive patients receiving cangrelor from January 2018 to March 2024. Transition to oral P2Y12 inhibitors (ticagrelor, clopidogrel, or prasugrel) followed institutional protocols based on guidelines and expert consensus. The primary endpoint was in-hospital major adverse cardiac and cerebrovascular events (MACCE), including myocardial infarction, stroke, and all-cause death. Among 493 patients, 78.7% presented with ACS (29.6% STEMI; 14.8% cardiogenic shock) and 79.3% underwent complex PCI. Of these, 80.5% were subsequently transitioned to ticagrelor (N=397) and 19.5% to a thienopyridine (clopidogrel N=85, prasugrel N=11). MACCE incidence was 12.6%, while bleeding occurred in 4.3%. A lower risk of MACCE was associated with transition to ticagrelor (9.8% vs. 24.0%; adjusted OR 0.35, 95%CI 0.20-0.62, p < 0.001) and adherence to protocol for transition to oral P2Y12 inhibitors (10.9% vs. 19.4%; adjusted OR 0.51, 95%CI 0.28-0.94). Extended low-dose cangrelor infusion was well-tolerated in critically ill patients requiring prolonged parenteral antiplatelet therapy. Overall, the SMILE study demonstrated that adherence to standardized transition protocols enhances clinical outcomes in high-risk PCI patients receiving cangrelor, particularly when transitioned to ticagrelor. Further research is needed to validate these results across diverse populations and clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionPurinergic P2Y Receptor AntagonistsPlatelet Aggregation InhibitorsAdenosine MonophosphateAcute Coronary SyndromeHumansMaleFemaleRetrospective StudiesAgedMiddle AgedRegistriesHemorrhageTime FactorsPrasugrel HydrochlorideTicagrelorClopidogrel

Stichwörter der Autor:innen

Acute coronary syndromeCangrelorComplex PCIP2Y12 inhibitorsPercutaneous coronary intervention

Substanzen

cangrelorPurinergic P2Y Receptor AntagonistsPlatelet Aggregation InhibitorsAdenosine MonophosphatePrasugrel HydrochlorideTicagrelorClopidogrel

Autor:innen und Institutionen

  • The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY, 10029, USA.
  • Department of Biomedical Sciences, Pieve Emanuele (MI), Humanitas University, Milan, Italy.
  • Department of Experimental and Clinical Medicine, School of Human Health Sciences, Careggi University Hospital, University of Florence, Florence, 50134, Italy.
  • Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Cardio Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY, 10029, USA. roxana.mehran@mountsina…

Förderung

  • Deutsche Herzstiftung
  • Chiesi USA

Zitieren

APA

Oliva, A., Cao, D., Shneyderman, M., Serrao, G., Gitto, M., Di Muro, F. M., Sartori, S., Feng, Y., Vogel, B., Nicolas, J., Sweeny, J., Krishnan, P., Bay, B., Johnson, J., Melarcode, P., Stefanini, G., Moreno, P., Kini, A., Dangas, G., …, & Mehran, R. (2025). Timing, indications and transition patterns associated with cangrelor use in patients undergoing PCI. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-025-03136-9

Vancouver

Oliva A, Cao D, Shneyderman M, Serrao G, Gitto M, Di Muro FM, et al. Timing, indications and transition patterns associated with cangrelor use in patients undergoing PCI. Journal of Thrombosis and Thrombolysis. 2025. doi:10.1007/s11239-025-03136-9

BibTeX
@article{Oliva2025,
  author = {Oliva, Angelo and Cao, Davide and Shneyderman, Mark and Serrao, Gregory and Gitto, Mauro and Di Muro, Francesca Maria and Sartori, Samantha and Feng, Yihan and Vogel, Birgit and Nicolas, Johny and Sweeny, Joseph and Krishnan, Prakash and Bay, Benjamin and Johnson, James and Melarcode, Parasuram and Stefanini, Giulio and Moreno, Pedro and Kini, Annapoorna and Dangas, George and Sharma, Samin and Mehran, Roxana},
  title = {Timing, indications and transition patterns associated with cangrelor use in patients undergoing PCI},
  journal = {Journal of Thrombosis and Thrombolysis},
  year = {2025},
  doi = {10.1007/s11239-025-03136-9}
}
Kostenlos starten →